RT Journal Article
SR Electronic
T1 CDX-2 immunostaining in primary and secondary ovarian carcinomas
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 641
OP 643
DO 10.1136/jcp.2003.013615
VO 57
IS 6
A1 Tornillo, L
A1 Moch, H
A1 Diener, P-A
A1 Lugli, A
A1 Singer, G
YR 2004
UL http://jcp.bmj.com/content/57/6/641.abstract
AB Aims: To assess the value of homeobox protein CDX-2 expression in the distinction between primary ovarian carcinomas and carcinomas metastatic to the ovary. Methods: CDX-2 expression was assessed by immunohistochemistry in 120 serous, 68 endometrioid, 24 clear cell, and 16 mucinous carcinomas of the ovary. In addition, CDX-2 immunoreactivity was investigated in 20 metastases from adenocarcinomas to the ovary (15 of colorectal, two of gastric, one of appendiceal, one of pancreatic, and one of cervical origin) and their corresponding primary tumours. Results: Almost all of the primary ovarian carcinomas lacked immunoreactivity for CDX-2. In contrast, 14 of the 16 metastases to the ovary from intestinal primaries showed CDX-2 immunoexpression. Conclusion: CDX-2 is a useful marker for differentiating primary ovarian carcinoma from carcinomas metastatic to the ovary.